Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, CICC Research Analyst Says

Eli Lilly and Company (NYSE:LLY) had its price target hoisted by CICC Research from $801.00 to $1,060.00 in a report issued on Thursday,MarketScreener reports. The firm presently has a “neutral” rating on the stock. CICC Research’s price target points to a potential upside of 3.45% from the company’s previous close.

A number of other equities analysts also recently issued reports on LLY. Morgan Stanley raised their price target on Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the stock an “overweight” rating in a research note on Thursday. Berenberg Bank reissued a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,015.11.

Eli Lilly and Company Stock Performance

LLY traded up $1.80 during midday trading on Thursday, hitting $1,024.67. 3,859,587 shares of the company traded hands, compared to its average volume of 4,072,967. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $968.70 billion, a PE ratio of 66.97, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company’s 50-day moving average is $826.89 and its 200 day moving average is $780.87. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,033.62.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Large investors have recently made changes to their positions in the business. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter worth about $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $27,000. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $29,000. Steph & Co. increased its position in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the last quarter. Finally, Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at $31,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.